{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:58:44Z","timestamp":1785560324449,"version":"3.56.0"},"reference-count":122,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"FEDER-Fundo Europeu de Desenvolvimento Regional funds"},{"name":"FCT-Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","award":["PTDC\/BIAMOL\/3986\/2021"],"award-info":[{"award-number":["PTDC\/BIAMOL\/3986\/2021"]}]},{"award":["PTDC\/BIAMOL\/3986\/2021"],"award-info":[{"award-number":["PTDC\/BIAMOL\/3986\/2021"]}],"id":[{"id":"https:\/\/ror.org\/00snfqn58","id-type":"ROR","asserted-by":"publisher"}]},{"name":"FCT","award":["UI\/BD\/153041\/2022"],"award-info":[{"award-number":["UI\/BD\/153041\/2022"]}]},{"name":"Liga Portuguesa Contra o Cancro\u2014N\u00facleo Regional do Norte","award":["Bolsas LPCC-NRN 2026"],"award-info":[{"award-number":["Bolsas LPCC-NRN 2026"]}]},{"award":["Bolsas LPCC-NRN 2026"],"award-info":[{"award-number":["Bolsas LPCC-NRN 2026"]}],"id":[{"id":"https:\/\/ror.org\/03r31ar10","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Institute for Research and Innovation in Health Sciences","award":["POCI-01-0145-FEDER-007274"],"award-info":[{"award-number":["POCI-01-0145-FEDER-007274"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Prostate cancer (PC) exhibits marked disparities in incidence and mortality across ethnicities, with men of Sub-Saharan African (SSA) ancestry experiencing 1.7 and 2.0 times higher values, respectively, than European men (EUR). However, SSA preclinical models remain scarce (just one commercial cell line). In this study, we established and characterized a novel panel of PC cell lines derived from SSA patients using conditional reprogramming (CR), a method that enables efficient propagation of primary cells while maintaining their genotypic and phenotypic features. Methods: CR was applied to five SSA-PC samples, and successfully propagated samples were authenticated by STR and ~1 million SNP profiling, and extensively characterized for proliferative capacity, migratory behaviour, karyotyping and epithelial and prostate tumour lineage markers. To explore drug response profiles, a high-throughput screen (HTS) of 1280 clinically annotated compounds was conducted. Results: Three SSA-PC cell lines were successfully established and authenticated, and five potential drug hits were validated. A new finding was the reduced sensitivity of SSA-derived models (9.0 times difference compared to commercial EUR PC cell lines) to camptothecin, a TOP1 inhibitor, while being equally sensitive to epirubicin hydrochloride, a TOP2 inhibitor. The cardiac glycoside digoxin, anthelmintic pyrvinium pamoate and antirheumatic agent auranofin were also efficient drugs in the in vitro testing. Conclusions: These results support the relevance of SSA-derived PC models for preclinical drug screening and highlight the value of including ancestry-diverse models in oncobiology research.<\/jats:p>","DOI":"10.3390\/cancers18152452","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:32:13Z","timestamp":1785403933000},"page":"2452","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sub-Saharan African Prostate Cancer Patient-Derived Cell Lines and High-Throughput Drug Screening: Addressing Ancestry Underrepresentation in Oncobiology Research"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0960-4818","authenticated-orcid":false,"given":"Carla S.","family":"Dos Santos","sequence":"first","affiliation":[{"name":"i3S\u2014Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto, 4200-135 Porto, Portugal"},{"name":"IPATIMUP\u2014Instituto de Patologia e Imunologia Molecular da Universidade do Porto, 4200-135 Porto, Portugal"},{"name":"ICBAS\u2014Instituto de Ci\u00eancias Biom\u00e9dicas Abel Salazar, Universidade do Porto, 4050-313 Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana C.","family":"Magalh\u00e3es","sequence":"additional","affiliation":[{"name":"i3S\u2014Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto, 4200-135 Porto, Portugal"},{"name":"IPATIMUP\u2014Instituto de Patologia e Imunologia Molecular da Universidade do Porto, 4200-135 Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3873-2034","authenticated-orcid":false,"given":"Veronica","family":"Fernandes","sequence":"additional","affiliation":[{"name":"i3S\u2014Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto, 4200-135 Porto, Portugal"},{"name":"IPATIMUP\u2014Instituto de Patologia e Imunologia Molecular da Universidade do Porto, 4200-135 Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6427-1374","authenticated-orcid":false,"given":"Ant\u00f3nio","family":"Pombinho","sequence":"additional","affiliation":[{"name":"i3S\u2014Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto, 4200-135 Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lurdes","family":"Torres","sequence":"additional","affiliation":[{"name":"Instituto Portugu\u00eas de Oncologia do Porto, 4200-072 Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5918-8621","authenticated-orcid":false,"given":"Margarida","family":"Andr\u00e9","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade Almada-Seixal, 2805-267 Almada, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelaide","family":"Sousa","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade Almada-Seixal, 2805-267 Almada, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Sequeira","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade Almada-Seixal, 2805-267 Almada, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Pinto","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade Almada-Seixal, 2805-267 Almada, Portugal"},{"name":"NOVA Medical School, NOVA University of Lisbon, 1169-056 Lisboa, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e1udia","family":"Pereira","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade Almada-Seixal, 2805-267 Almada, Portugal"},{"name":"Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7550-8285","authenticated-orcid":false,"given":"Paulo M.","family":"Costa","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade Almada-Seixal, 2805-267 Almada, Portugal"},{"name":"Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00facio Lara","family":"Santos","sequence":"additional","affiliation":[{"name":"Instituto Portugu\u00eas de Oncologia do Porto, 4200-072 Porto, Portugal"},{"name":"ONCOCIR\u2014Education and Care in Oncology, PALOP\u2014Lusophone Africa, 4200-072 Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4271-1527","authenticated-orcid":false,"given":"Luisa","family":"Pereira","sequence":"additional","affiliation":[{"name":"i3S\u2014Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto, 4200-135 Porto, Portugal"},{"name":"IPATIMUP\u2014Instituto de Patologia e Imunologia Molecular da Universidade do Porto, 4200-135 Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s41576-020-00306-8","article-title":"African genetic diversity and adaptation inform a precision medicine agenda","volume":"22","author":"Pereira","year":"2021","journal-title":"Nat. Rev. Genet."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"dos Santos, C.S., Magalh\u00e3es, A.C., Pinto, R.J., Carrilho, C., Pereira, C., Miguel, F., Borges, P., Santos, L.L., and Pereira, L. (2025). Addressing Ancestral Underrepresentation in Oncobiology: The Need for Sub-Saharan African-Specific In Vitro Models. Genes, 16.","DOI":"10.3390\/genes16121403"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"102391","DOI":"10.1016\/j.tranon.2025.102391","article-title":"A new dawn: Vitalising translational oncology research in Africa with the help of advanced cell culture models","volume":"56","author":"Klima","year":"2025","journal-title":"Transl. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"R138","DOI":"10.1093\/hmg\/ddab001","article-title":"Sub-Saharan African information potential to unveil adaptations to infectious disease","volume":"30","author":"Pedro","year":"2021","journal-title":"Hum. Mol. Genet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.cell.2019.02.033","article-title":"Human Immunology through the Lens of Evolutionary Genetics","volume":"177","year":"2019","journal-title":"Cell"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s13023-022-02391-w","article-title":"Increasing African genomic data generation and sharing to resolve rare and undiagnosed diseases in Africa: A call-to-action by the H3Africa rare diseases working group","volume":"17","author":"Lumaka","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/s41576-019-0144-0","article-title":"Genomics of disease risk in globally diverse populations","volume":"20","author":"Gurdasani","year":"2019","journal-title":"Nat. Rev. Genet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/jamaoncol.2016.1854","article-title":"Racial\/Ethnic Disparities in Genomic Sequencing","volume":"2","author":"Spratt","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1158\/0008-5472.CAN-18-2747","article-title":"An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines","volume":"79","author":"Dutil","year":"2019","journal-title":"Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.stemcr.2017.03.012","article-title":"iPSCORE: A Resource of 222 iPSC Lines Enabling Functional Characterization of Genetic Variation across a Variety of Cell Types","volume":"8","author":"Panopoulos","year":"2017","journal-title":"Stem Cell Rep."},{"key":"ref_11","unstructured":"(2024). The All of Us Research Program Genomics Investigators. Genomic data in the All of Us Research Program. Nature, 627, 340\u2013346."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1038\/s41467-021-22207-y","article-title":"Genetic substructure and complex demographic history of South African Bantu speakers","volume":"12","author":"Sengupta","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41586-020-2859-7","article-title":"High-depth African genomes inform human migration and health","volume":"586","author":"Choudhury","year":"2020","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ajhg.2020.07.007","article-title":"High Levels of Genetic Diversity within Nilo-Saharan Populations: Implications for Human Adaptation","volume":"107","author":"Mulindwa","year":"2020","journal-title":"Am. J. Hum. Genet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1007\/s00125-025-06395-6","article-title":"Genome-wide association study identifying novel risk variants associated with glycaemic traits in the continental African AWI-Gen cohort","volume":"68","author":"Chebii","year":"2025","journal-title":"Diabetologia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41431-023-01521-7","article-title":"Genome, HLA and polygenic risk score analyses for prevalent and persistent cervical human papillomavirus (HPV) infections","volume":"32","author":"Adebamowo","year":"2024","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1038\/s41467-022-30098-w","article-title":"Meta-analysis of sub-Saharan African studies provides insights into genetic architecture of lipid traits","volume":"13","author":"Choudhury","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"10325","DOI":"10.1038\/s41598-025-94707-6","article-title":"Coding and regulatory somatic profiling of triple-negative breast cancer in Sub-Saharan African patients","volume":"15","author":"Pinto","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1038\/s41467-018-06616-0","article-title":"Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features","volume":"9","author":"Pitt","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_20","first-page":"831","article-title":"Analysis of the genomic landscapes of Barbadian and Nigerian women with triple negative breast cancer","volume":"33","author":"Hercules","year":"2022","journal-title":"Cancer Causes Control"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41586-022-05154-6","article-title":"African-specific molecular taxonomy of prostate cancer","volume":"609","author":"Jaratlerdsiri","year":"2022","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13073-022-01096-w","article-title":"Genome-wide interrogation of structural variation reveals novel African-specific prostate cancer oncogenic drivers","volume":"14","author":"Gong","year":"2022","journal-title":"Genome Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1038\/s41588-024-01931-3","article-title":"Heterogeneous genetic architectures of prostate cancer susceptibility in sub-Saharan Africa","volume":"56","author":"Janivara","year":"2024","journal-title":"Nat. Genet."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41586-025-09935-7","article-title":"Enriching African genome representation through the AGenDA project","volume":"649","author":"Ramsay","year":"2026","journal-title":"Nature"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"103970","DOI":"10.1016\/j.xpro.2025.103970","article-title":"Protocol for the establishment and characterization of South African patient-derived intestinal organoids","volume":"6","author":"Abdulla","year":"2025","journal-title":"STAR. Protoc."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"9160","DOI":"10.1038\/s41598-025-93634-w","article-title":"The first-in-Africa ex vivo drug sensitivity testing platform identifies novel drug combinations for South African leukaemia patient cohort","volume":"15","author":"Kenmogne","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"key":"ref_28","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nprot.2016.174","article-title":"Conditional reprogramming and long-term expansion of normal and tumor cells from human biospecimens","volume":"12","author":"Liu","year":"2017","journal-title":"Nat. Protoc."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"20035","DOI":"10.1073\/pnas.1213241109","article-title":"Conditionally reprogrammed cells represent a stem-like state of adult epithelial cells","volume":"109","author":"Suprynowicz","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_31","unstructured":"Partin, A.W., Dmochowski, R.R., Kavoussi, L.R., Peters, C.A., and Wein, A.J. (2025). Campbell-Walsh-Wein Urology, Elsevier. [13th ed.]. Available online: https:\/\/shop.elsevier.com\/books\/campbell-walsh-wein-urology\/dmochowski\/978-0-323-88405-1."},{"key":"ref_32","unstructured":"EAU Guidelines Office (2025). EAU Guidelines on Prostate Cancer, EAU Guidelines Office. [2025th ed.]. Available online: https:\/\/uroweb.org\/guidelines\/prostate-cancer."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"22741","DOI":"10.18632\/oncotarget.13937","article-title":"Conditionally reprogrammed normal and primary tumor prostate epithelial cells: A novel patient-derived cell model for studies of human prostate cancer","volume":"8","author":"Timofeeva","year":"2017","journal-title":"Oncotarget"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/ijc.32639","article-title":"CLASTR: The Cellosaurus STR similarity search tool\u2014A precious help for cell line authentication","volume":"146","author":"Robin","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1101\/gr.094052.109","article-title":"Fast model-based estimation of ancestry in unrelated individuals","volume":"19","author":"Alexander","year":"2009","journal-title":"Genome Res."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"The 1000 Genomes Project Consortium (2015). A global reference for human genetic variation. Nature, 526, 68\u201374.","DOI":"10.1038\/nature15393"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ajhg.2013.06.020","article-title":"RFMix: A discriminative modeling approach for rapid and robust local-ancestry inference","volume":"93","author":"Maples","year":"2013","journal-title":"Am. J. Hum. Genet."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nmeth.1785","article-title":"A linear complexity phasing method for thousands of genomes","volume":"9","author":"Delaneau","year":"2011","journal-title":"Nat. Methods"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"The International HapMap Consortium (2007). A second generation human haplotype map of over 3.1 million SNPs. Nature, 449, 851\u2013861.","DOI":"10.1038\/nature06258"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"W58","DOI":"10.1093\/nar\/gkw233","article-title":"HaploGrep 2: Mitochondrial haplogroup classification in the era of high-throughput sequencing","volume":"44","author":"Weissensteiner","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Poznik, G.D. (2016). Identifying Y-chromosome haplogroups in arbitrarily large samples of sequenced or genotyped men. bioRxiv.","DOI":"10.1101\/088716"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1128\/aem.58.8.2606-2615.1992","article-title":"Genus- and species-specific identification of mycoplasmas by 16S rRNA amplification","volume":"58","author":"Angulo","year":"1992","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.cancergencyto.2008.07.008","article-title":"Cryptic chromosome rearrangement resulting in SYT-SSX2 fusion gene in a monophasic synovial sarcoma","volume":"187","author":"Torres","year":"2008","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00439-009-0726-6","article-title":"ISCN 2009 an international system for human cytogenetic nomenclature","volume":"126","author":"Willatt","year":"2009","journal-title":"Hum. Genet."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/em.10207","article-title":"Population doubling: A simple and more accurate estimation of cell growth suppression in the in vitro assay for chromosomal aberrations that reduces irrelevant positive results","volume":"43","author":"Greenwood","year":"2004","journal-title":"Environ. Mol. Mutagen."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2809192","DOI":"10.1155\/2016\/2809192","article-title":"Differential Proteomic Analysis of Human Placenta-Derived Mesenchymal Stem Cells Cultured on Normal Tissue Culture Surface and Hyaluronan-Coated Surface","volume":"2016","author":"Wong","year":"2016","journal-title":"Stem Cells Int."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat. Methods"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: An open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat. Methods"},{"key":"ref_49","first-page":"e66860","article-title":"Assay Development for High-Throughput Drug Screening Against Mycobacteria","volume":"212","author":"Oliveira","year":"2024","journal-title":"J. Vis. Exp."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Padua, D., Barros, R., Amaral, A.L., Mesquita, P., Freire, A.F., Sousa, M., Maia, A.F., Caiado, I., Fernandes, H., and Pombinho, A. (2020). A SOX2 Reporter System Identifies Gastric Cancer Stem-Like Cells Sensitive to Monensin. Cancers, 12.","DOI":"10.3390\/cancers12020495"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"D1265","DOI":"10.1093\/nar\/gkad976","article-title":"DrugBank 6.0: The DrugBank Knowledgebase for 2024","volume":"52","author":"Knox","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.fsigen.2018.10.020","article-title":"Identification and molecular characterisation of an AMEL-X null allele due to an Alu insertion","volume":"38","author":"Bonito","year":"2019","journal-title":"Forensic Sci. Int. Genet."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/PAP.0000000000000256","article-title":"An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin","volume":"27","author":"Bellizzi","year":"2020","journal-title":"Adv. Anat. Pathol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/sj.bjc.6604951","article-title":"Ki-67 and outcome in clinically localised prostate cancer: Analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study","volume":"100","author":"Berney","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0094-0143(03)00057-0","article-title":"PSA markers in prostate cancer detection","volume":"30","author":"Gretzer","year":"2003","journal-title":"Urol. Clin. N. Am."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Jiang, N., Zhu, S., Chen, J., Niu, Y., and Zhou, L. (2013). A-methylacyl-CoA racemase (AMACR) and prostate-cancer risk: A meta-analysis of 4385 participants. PLoS ONE, 8.","DOI":"10.1371\/annotation\/677fdf34-651e-4dc8-a0be-d0d633237a85"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/s41597-024-03869-x","article-title":"High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma","volume":"11","author":"Pishas","year":"2024","journal-title":"Sci. Data"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1177\/1087057113499405","article-title":"An HTS-compatible 3D colony formation assay to identify tumor-specific chemotherapeutics","volume":"18","author":"Horman","year":"2013","journal-title":"J. Biomol. Screen."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1001\/jamaoncol.2018.6634","article-title":"Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity","volume":"5","author":"Feijen","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10557-016-6711-0","article-title":"Anthracycline Chemotherapy and Cardiotoxicity","volume":"31","author":"McGowan","year":"2017","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Schultz, C.W., and Nevler, A. (2022). Pyrvinium Pamoate: Past, Present, and Future as an Anti-Cancer Drug. Biomedicines, 10.","DOI":"10.3390\/biomedicines10123249"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/bjc.1997.272","article-title":"Enhancement of paclitaxel activity against hormone-refractory prostate cancer cells in vitro and in vivo by quinacrine","volume":"75","author":"Castillo","year":"1997","journal-title":"Br. J. Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.semcancer.2019.09.021","article-title":"Repurposing quinacrine for treatment-refractory cancer","volume":"68","author":"Oien","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.4103\/jcrt.jcrt_902_22","article-title":"Quinacrine enhances the efficacy of cisplatin by increasing apoptosis and modulating cancer survival proteins in a colorectal cancer cell line","volume":"19","author":"Islam","year":"2023","journal-title":"J. Cancer Res. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.3892\/ol.2017.6569","article-title":"Repurposing itraconazole for the treatment of cancer","volume":"14","author":"Pounds","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Lima, T.S., Souza, L.O., Iglesias-Gato, D., Elversang, J., Jorgensen, F.S., Kallunki, T., Roder, M.A., Brasso, K., and Moreira, J.M.A. (2022). Itraconazole Reverts ABCB1-Mediated Docetaxel Resistance in Prostate Cancer. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.869461"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"342","DOI":"10.2174\/1871523018666190911121306","article-title":"Tegaserod for the Treatment of Irritable Bowel Syndrome","volume":"19","author":"Madia","year":"2020","journal-title":"Anti-Inflamm. Anti-Allergy Agents Med. Chem."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e682","DOI":"10.1016\/j.cgh.2021.05.040","article-title":"Re-evaluation of the Cardiovascular Safety Profile of Tegaserod: A Review of the Clinical Data","volume":"20","author":"Lacy","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7171\/jbt.18-2902-002","article-title":"The Cellosaurus, a Cell-Line Knowledge Resource","volume":"29","author":"Bairoch","year":"2018","journal-title":"J. Biomol. Tech."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Richardsen, E., Andersen, S., Al-Saad, S., Rakaee, M., Nordby, Y., Pedersen, M.I., Ness, N., Grindstad, T., Movik, I., and Donnem, T. (2017). Evaluation of the proliferation marker Ki-67 in a large prostatectomy cohort. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0186852"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/pcan.2016.12","article-title":"Prognostic value of Ki67 in localized prostate carcinoma: A multi-institutional study of >1000 prostatectomies","volume":"19","author":"Tretiakova","year":"2016","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1515\/raon-2016-0033","article-title":"The proliferation marker Ki67, but not neuroendocrine expression, is an independent factor in the prediction of prognosis of primary prostate cancer patients","volume":"50","author":"Pascale","year":"2016","journal-title":"Radiol. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s00345-014-1421-3","article-title":"Multi-institutional validation of the prognostic value of Ki-67 labeling index in patients treated with radical prostatectomy","volume":"33","author":"Mathieu","year":"2015","journal-title":"World J. Urol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3892\/ol.2021.12481","article-title":"Hsa_circ_0076305 induces migration-proliferation dichotomy in gastric cancer","volume":"21","author":"Zhang","year":"2021","journal-title":"Oncol. Lett."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"34796","DOI":"10.1038\/srep34796","article-title":"Fractionated radiation exposure amplifies the radioresistant nature of prostate cancer cells","volume":"6","author":"McDermott","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Molter, C.W., Muszynski, E.F., Tao, Y., Trivedi, T., Clouvel, A., and Ehrlicher, A.J. (2022). Prostate cancer cells of increasing metastatic potential exhibit diverse contractile forces, cell stiffness, and motility in a microenvironment stiffness-dependent manner. Front. Cell Dev. Biol., 10.","DOI":"10.3389\/fcell.2022.932510"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Lim, E.Y., Park, J., Kim, Y.T., and Kim, M.J. (2020). Imipramine Inhibits Migration and Invasion in Metastatic Castration-Resistant Prostate Cancer PC-3 Cells via AKT-Mediated NF-\u03baB Signaling Pathway. Molecules, 25.","DOI":"10.3390\/molecules25204619"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/modpathol.2014.77","article-title":"Comparison of different prostatic markers in lymph node and distant metastases of prostate cancer","volume":"28","author":"Queisser","year":"2015","journal-title":"Mod. Pathol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"235","DOI":"10.4132\/jptm.2025.04.16","article-title":"AMACR is a highly sensitive and specific immunohistochemical marker for diagnosing prostate cancer on biopsy: A systematic review and meta-analysis","volume":"59","author":"Prihadi","year":"2025","journal-title":"J. Pathol. Transl. Med."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Badrane, I., Castello, A., Brunelli, M., Cittanti, C., Adamantiadis, S., Bagni, I., Mindicini, N., Lancia, F., Castellani, M., and Uccelli, L. (2024). Atypical Metastases from Prostate Cancer: Alpha-Methylacyl-Coenzyme A Racemase (AMACR) as a Potential Molecular Target in Prostate-Specific Membrane Antigen-Negative Prostate Adenocarcinoma. Biomolecules, 15.","DOI":"10.3390\/biom15010017"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1097\/00000478-200207000-00012","article-title":"Alpha-Methylacyl-CoA racemase: A novel tumor marker over-expressed in several human cancers and their precursor lesions","volume":"26","author":"Zhou","year":"2002","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12943-015-0364-7","article-title":"Long noncoding RNA, CCDC26, controls myeloid leukemia cell growth through regulation of KIT expression","volume":"14","author":"Hirano","year":"2015","journal-title":"Mol. Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s10528-019-09911-7","article-title":"Genetic Polymorphisms of CCDC26 rs891835, rs6470745, and rs55705857 in Glioma Risk: A Systematic Review and Meta-analysis","volume":"57","year":"2019","journal-title":"Biochem. Genet."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/neuonc\/noac279","article-title":"Australian genome-wide association study confirms higher female risk for adult glioma associated with variants in the region of CCDC26","volume":"25","author":"Alpen","year":"2023","journal-title":"Neuro Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.biopha.2016.06.059","article-title":"Long noncoding RNA CCDC26 as a potential predictor biomarker contributes to tumorigenesis in pancreatic cancer","volume":"83","author":"Peng","year":"2016","journal-title":"Biomed. Pharmacother."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"954870","DOI":"10.1155\/2015\/954870","article-title":"The MicroRNA3686 Inhibits the Proliferation of Pancreas Carcinoma Cell Line by Targeting the Polo-Like Kinase 1","volume":"2015","author":"Jin","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/nature13311","article-title":"PVT1 dependence in cancer with MYC copy-number increase","volume":"512","author":"Tseng","year":"2014","journal-title":"Nature"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Yakkala, P.A., Penumallu, N.R., Shafi, S., and Kamal, A. (2023). Prospects of Topoisomerase Inhibitors as Promising Anti-Cancer Agents. Pharmaceuticals, 16.","DOI":"10.3390\/ph16101456"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrc2608","article-title":"DNA topoisomerase II and its growing repertoire of biological functions","volume":"9","author":"Nitiss","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"20474","DOI":"10.18632\/oncotarget.4105","article-title":"Catalytic inhibitors of DNA topoisomerase II suppress the androgen receptor signaling and prostate cancer progression","volume":"6","author":"Li","year":"2015","journal-title":"Oncotarget"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Schaefer-Klein, J.L., Murphy, S.J., Johnson, S.H., Vasmatzis, G., and Kovtun, I.V. (2015). Topoisomerase 2 Alpha Cooperates with Androgen Receptor to Contribute to Prostate Cancer Progression. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0142327"},{"key":"ref_92","first-page":"6066","article-title":"Induction of oxidative stress by anticancer drugs in the presence and absence of cells","volume":"14","author":"Yokoyama","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/s41420-024-02095-z","article-title":"Epirubicin induces cardiotoxicity through disrupting ATP6V0A2-dependent lysosomal acidification and triggering ferroptosis in cardiomyocytes","volume":"10","author":"Zhang","year":"2024","journal-title":"Cell Death Discov."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Matias-Barrios, V.M., and Dong, X. (2023). The Implication of Topoisomerase II Inhibitors in Synthetic Lethality for Cancer Therapy. Pharmaceuticals, 16.","DOI":"10.3390\/ph16010094"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.molcel.2021.11.016","article-title":"MYC assembles and stimulates topoisomerases 1 and 2 in a \u201ctopoisome\u201d","volume":"82","author":"Das","year":"2022","journal-title":"Mol. Cell"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1634\/theoncologist.2-6-359","article-title":"Topoisomerase I Inhibitors","volume":"2","author":"Ewesuedo","year":"1997","journal-title":"Oncologist"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"43733","DOI":"10.18632\/oncotarget.16376","article-title":"Camptothecin resistance is determined by the regulation of topoisomerase I degradation mediated by ubiquitin proteasome pathway","volume":"8","author":"Ando","year":"2017","journal-title":"Oncotarget"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Taylor, M.J., Collins, J.M., Montalvo, A.D., and Wang, D. (2025). Association Between UGT1A1 mRNA Expression and Cis-Acting Genetic Variants and Trans-Acting Transcriptional Regulators in Human Liver Samples. Genes, 16.","DOI":"10.3390\/genes16080971"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"9521","DOI":"10.1007\/s00210-024-03285-3","article-title":"\u201cCardiac glycosides\u201d\u2014Quo vaditis?\u2014Past, present, and future?","volume":"397","author":"Fender","year":"2024","journal-title":"Naunyn Schmiedeb. Arch. Pharmacol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/jb\/mvad085","article-title":"Involvement of cardiac glycosides targeting Na\/K-ATPase in their inhibitory effects on c-Myc expression via its transcription, translation and proteasomal degradation","volume":"175","author":"Tokugawa","year":"2023","journal-title":"J. Biochem."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s00018-023-04910-9","article-title":"The mechanistic role of cardiac glycosides in DNA damage response and repair signaling","volume":"80","author":"Ainembabazi","year":"2023","journal-title":"Cell Mol. Life Sci."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/2159-8274.CD-10-0020","article-title":"A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment","volume":"1","author":"Platz","year":"2011","journal-title":"Cancer Discov."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e14217","DOI":"10.1111\/and.14217","article-title":"Digoxin reduces the incidence of prostate cancer but increases the cancer-specific mortality: A systematic review and pooled analysis","volume":"53","author":"Zhao","year":"2021","journal-title":"Andrologia"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0014-2999(03)01825-9","article-title":"Effects of intermediate-conductance Ca2+-activated K+ channel modulators on human prostate cancer cell proliferation","volume":"471","author":"Parihar","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"ref_105","first-page":"21","article-title":"A pilot phase II Study of digoxin in patients with recurrent prostate cancer as evident by a rising PSA","volume":"2","author":"Lin","year":"2014","journal-title":"Am. J. Cancer Ther. Pharmacol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.21873\/anticanres.17672","article-title":"A Novel Three Small Molecule Inhibitor Combination Therapy For Prostate Cancer","volume":"45","author":"Demir","year":"2025","journal-title":"Anticancer Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1002\/jcp.26006","article-title":"The novel role of pyrvinium in cancer therapy","volume":"233","author":"Abdollahi","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1080\/15287394.2014.955834","article-title":"Auranofin promotes mitochondrial apoptosis by inducing annexin A5 expression and translocation in human prostate cancer cells","volume":"77","author":"Park","year":"2014","journal-title":"J. Toxicol. Environ. Health Part A"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s12672-021-00439-0","article-title":"The gold complex auranofin: New perspectives for cancer therapy","volume":"12","author":"Abdalbari","year":"2021","journal-title":"Discov. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1158\/1078-0432.CCR-06-0067","article-title":"Mechanisms underlying the development of androgen-independent prostate cancer","volume":"12","author":"Pienta","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1677\/ERC-08-0084","article-title":"Androgen receptor and growth factor signaling cross-talk in prostate cancer cells","volume":"15","author":"Zhu","year":"2008","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Menbari Oskouie, I., Khatami, F., Shiralizadeh Dezfuli, A., Mashhadi, R., Mirzaei, A., Hashemi Dougaheh, S.N., Azodian Ghajar, H., Heshmat, R., and Aghamir, S.M.K. (2025). Reducing the effective dosage of flutamide on prostate cancer cell lines through combination with selenium nanoparticles: An in-vitro study. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0318483"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"127817","DOI":"10.1016\/j.bmcl.2021.127817","article-title":"Synthesis, biological evaluation and X-ray analysis of bicalutamide sulfoxide analogues for the potential treatment of prostate cancer","volume":"36","author":"Kandil","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"108007","DOI":"10.1016\/j.compbiolchem.2023.108007","article-title":"Targeting AR-positive breast cancer cells via drug repurposing approach","volume":"108","author":"Dutta","year":"2024","journal-title":"Comput. Biol. Chem."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Chen, Q.H. (2023). Crosstalk between Microtubule Stabilizing Agents and Prostate Cancer. Cancers, 15.","DOI":"10.3390\/cancers15133308"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"101959","DOI":"10.1016\/j.jddst.2020.101959","article-title":"Docetaxel: An update on its molecular mechanisms, therapeutic trajectory and nanotechnology in the treatment of breast, lung and prostate cancer","volume":"60","author":"Imran","year":"2020","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"117572","DOI":"10.1016\/j.biopha.2024.117572","article-title":"Modulation of inflammatory mediators underlies the antitumor effect of the combination of morusin and docetaxel on prostate cancer cells","volume":"180","author":"Fadil","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Penata-Taborda, A., Espitia-Perez, P., Espitia-Perez, L., Coneo-Pretelt, A., Brango, H., Ricardo-Caldera, D., Arteaga-Arroyo, G., Jimenez-Vidal, L., Galeano-Paez, C., and Pastor-Sierra, K. (2025). Combination of Low-Dose Sulforaphane and Docetaxel on Mitochondrial Function and Metabolic Reprogramming in Prostate Cancer Cell Lines. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26031013"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jcp.20045","article-title":"Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 (\u2018Iressa\u2019) induces cell-cycle arrest and inhibits proliferation in prostate cancer cells","volume":"201","author":"Sgambato","year":"2004","journal-title":"J. Cell. Physiol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/COC.0b013e31818b946b","article-title":"An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer","volume":"32","author":"Pezaro","year":"2009","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/pros.20995","article-title":"Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro","volume":"69","author":"Festuccia","year":"2009","journal-title":"Prostate"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/s41416-020-01052-8","article-title":"EGFR as a stable marker of prostate cancer dissemination to bones","volume":"123","author":"Nastaly","year":"2020","journal-title":"Br. J. Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/15\/2452\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:26:12Z","timestamp":1785558372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/15\/2452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":122,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cancers18152452"],"URL":"https:\/\/doi.org\/10.3390\/cancers18152452","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]}}}